Clinical Trials · NCT03001349

68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

TerminatedEARLY_Phase 1Octreotide (Prohibited)
Phase
EARLY_Phase 1
Recruitment status
Terminated
Sponsor
M.D. Anderson Cancer Center
Enrollment
4
Start date
May 2017
Locations
1 site, United States
Primary endpoint
Incidence of adverse events
View Octreotide compound reference